[{"id":"9fb2cdde-012a-4d53-b589-d932fba3f768","acronym":"C2025-009-01","url":"https://clinicaltrials.gov/study/NCT07014878","created_at":"2025-06-14T13:55:09.580Z","updated_at":"2025-06-14T13:55:09.580Z","phase":"Phase 1","brief_title":"A Study of DCTY1102 Injection in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT07014878 - C2025-009-01","lead_sponsor":"Beijing DCTY Biotech Co.,Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-06-11"},{"id":"1387da34-72f6-46cd-8db5-48bc41fc9fe6","acronym":"AFNT211-22-101","url":"https://clinicaltrials.gov/study/NCT06105021","created_at":"2023-10-27T17:14:07.431Z","updated_at":"2025-02-25T13:55:42.802Z","phase":"Phase 1/2","brief_title":"Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor","source_id_and_acronym":"NCT06105021 - AFNT211-22-101","lead_sponsor":"Affini-T Therapeutics, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFNT-211"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/06/2024","start_date":" 03/06/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-02-20"},{"id":"168840e4-a367-4523-bec5-a87bb18a9b81","acronym":"NT-175-201","url":"https://clinicaltrials.gov/study/NCT05877599","created_at":"2023-05-26T15:07:05.809Z","updated_at":"2025-02-25T13:55:14.477Z","phase":"Phase 1","brief_title":"A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","source_id_and_acronym":"NCT05877599 - NT-175-201","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • HLA-A","pipe":" | ","alterations":" TP53 mutation • HLA-A*02:01","tags":["TP53 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • NT-175"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 08/01/2039","study_completion_date":" 08/01/2039","last_update_posted":"2025-02-20"},{"id":"f183e140-987d-476d-a6b5-4df9e4ffb873","acronym":"TCR-T","url":"https://clinicaltrials.gov/study/NCT05417932","created_at":"2022-06-14T22:56:30.934Z","updated_at":"2025-02-25T14:08:55.469Z","phase":"Phase 1/2","brief_title":"A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma","source_id_and_acronym":"NCT05417932 - TCR-T","lead_sponsor":"SCG Cell Therapy Pte. Ltd.","biomarkers":" STMN2","pipe":"","alterations":" ","tags":["STMN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCG101"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-18"},{"id":"65969d8a-b172-4873-a916-4494ff06814d","acronym":"IMA401-101","url":"https://clinicaltrials.gov/study/NCT05359445","created_at":"2022-05-03T14:54:12.020Z","updated_at":"2025-02-25T17:37:48.710Z","phase":"Phase 1","brief_title":"IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor","source_id_and_acronym":"NCT05359445 - IMA401-101","lead_sponsor":"Immatics Biotechnologies GmbH","biomarkers":" MAGEA4","pipe":" | ","alterations":" MAGEA4 expression • MAGEA4 overexpression","tags":["MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MAGEA4 expression • MAGEA4 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • IMA401"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 05/19/2022","start_date":" 05/19/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-01-28"},{"id":"57a461d0-704c-401d-b50c-fda397e12376","acronym":"","url":"https://clinicaltrials.gov/study/NCT06617000","created_at":"2025-02-26T14:59:12.446Z","updated_at":"2025-02-26T14:59:12.446Z","phase":"Phase 1","brief_title":"A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related","source_id_and_acronym":"NCT06617000","lead_sponsor":"SCG Cell Therapy Pte. Ltd.","biomarkers":" STMN2","pipe":"","alterations":" ","tags":["STMN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCG101"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-09-27"},{"id":"7f32c6ae-db00-48e3-960e-6cced44274a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05973487","created_at":"2023-08-03T15:09:34.671Z","updated_at":"2024-07-02T16:34:25.733Z","phase":"Phase 1","brief_title":"A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors","source_id_and_acronym":"NCT05973487","lead_sponsor":"TScan Therapeutics, Inc.","biomarkers":" HLA-A • PRAME • HLA-C","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A • PRAME • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/06/2024","start_date":" 05/06/2024","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-06-14"},{"id":"d026d8e4-9c91-4cee-be37-7c17094bbad4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06218914","created_at":"2024-01-23T17:20:10.961Z","updated_at":"2024-07-02T16:34:25.951Z","phase":"Phase 1","brief_title":"A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation","source_id_and_acronym":"NCT06218914","lead_sponsor":"Neogene Therapeutics, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 02/05/2024","start_date":" 02/05/2024","primary_txt":" Primary completion: 08/30/2025","primary_completion_date":" 08/30/2025","study_txt":" Completion: 01/02/2040","study_completion_date":" 01/02/2040","last_update_posted":"2024-06-14"},{"id":"74c31265-1520-4843-8d42-dcf55e82cdf5","acronym":"TSCAN-001","url":"https://clinicaltrials.gov/study/NCT05473910","created_at":"2022-07-26T17:09:59.782Z","updated_at":"2024-07-02T16:34:26.524Z","phase":"Phase 1","brief_title":"A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation","source_id_and_acronym":"NCT05473910 - TSCAN-001","lead_sponsor":"TScan Therapeutics, Inc.","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • HLA-A positive","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • TSC-100 • TSC-101"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-13"},{"id":"8009476b-712f-4b6f-9467-7f222bfb4fb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05450562","created_at":"2022-07-08T14:55:40.019Z","updated_at":"2024-07-02T16:35:00.176Z","phase":"Phase 1/2","brief_title":"Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05450562","lead_sponsor":"Sanofi","biomarkers":" ALK • GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["ALK • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Libtayo (cemiplimab-rwlc) • SAR444200"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 12/12/2030","primary_completion_date":" 12/12/2030","study_txt":" Completion: 12/12/2030","study_completion_date":" 12/12/2030","last_update_posted":"2024-05-30"},{"id":"1da77410-a879-4bd0-ac76-26adfb53609a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05989828","created_at":"2023-08-14T14:10:18.266Z","updated_at":"2024-07-02T16:35:01.088Z","phase":"Phase 1","brief_title":"A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer","source_id_and_acronym":"NCT05989828","lead_sponsor":"University of Southern California","biomarkers":" HER-2 • PD-L1 • ER • PGR • CTAG1B","pipe":" | ","alterations":" HER-2 negative • PGR negative","tags":["HER-2 • PD-L1 • ER • PGR • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-05-24"},{"id":"d5b7efa8-e965-442b-8575-71001ab87e87","acronym":"IGNYTE-ESO","url":"https://clinicaltrials.gov/study/NCT03967223","created_at":"2021-01-19T18:07:33.215Z","updated_at":"2024-07-02T16:35:07.685Z","phase":"Phase 2","brief_title":"Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors","source_id_and_acronym":"NCT03967223 - IGNYTE-ESO","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 08/28/2024","primary_completion_date":" 08/28/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-04-25"},{"id":"81497553-3d5a-49ef-8513-cf9cb5b29947","acronym":"","url":"https://clinicaltrials.gov/study/NCT05642455","created_at":"2022-12-08T14:57:33.766Z","updated_at":"2024-07-02T16:35:07.743Z","phase":"Phase 1/2","brief_title":"SPEARHEAD-3 Pediatric Study","source_id_and_acronym":"NCT05642455","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 07/30/2038","study_completion_date":" 07/30/2038","last_update_posted":"2024-04-24"},{"id":"aa19e127-4a6d-4543-94a8-fa9ef6096cb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05881525","created_at":"2023-05-31T15:05:39.768Z","updated_at":"2024-07-02T16:35:09.880Z","phase":"Phase 1","brief_title":"NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05881525","lead_sponsor":"TCRCure Biopharma Ltd.","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • N201"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-12"},{"id":"7fc864bc-2037-4926-9819-2552b751ef5d","acronym":"ATTAC-MCC","url":"https://clinicaltrials.gov/study/NCT03747484","created_at":"2021-06-30T14:53:31.876Z","updated_at":"2024-07-02T16:35:12.716Z","phase":"Phase 1/2","brief_title":"Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer","source_id_and_acronym":"NCT03747484 - ATTAC-MCC","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Bavencio (avelumab) • Actimmune (interferon gamma-1 b) • MCC1 TCR"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 07/03/2019","start_date":" 07/03/2019","primary_txt":" Primary completion: 01/10/2024","primary_completion_date":" 01/10/2024","study_txt":" Completion: 01/10/2025","study_completion_date":" 01/10/2025","last_update_posted":"2024-03-26"},{"id":"2c13cc26-0e5f-458f-80db-772216b113f8","acronym":"SPEARHEAD-1","url":"https://clinicaltrials.gov/study/NCT04044768","created_at":"2021-01-18T19:50:39.967Z","updated_at":"2024-07-02T16:35:18.934Z","phase":"Phase 2","brief_title":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","source_id_and_acronym":"NCT04044768 - SPEARHEAD-1","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 10/10/2021","primary_completion_date":" 10/10/2021","study_txt":" Completion: 04/01/2038","study_completion_date":" 04/01/2038","last_update_posted":"2024-02-19"},{"id":"55c21f83-a0e4-4e9b-947b-7ac8365bc89c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05787535","created_at":"2023-03-28T14:05:07.469Z","updated_at":"2024-07-02T16:35:21.209Z","phase":"Phase 1","brief_title":"HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor","source_id_and_acronym":"NCT05787535","lead_sponsor":"HRYZ Biotech Co.","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HRYZ-T101"],"overall_status":"Recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-02-02"},{"id":"ef8056a0-9ebe-4f7d-a6ed-854f7c1cbfe5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05952947","created_at":"2023-07-20T14:08:58.725Z","updated_at":"2024-07-02T16:35:21.083Z","phase":"Phase 1","brief_title":"HRYZ-T101 Injection for HPV18 Positive Solid Tumor","source_id_and_acronym":"NCT05952947","lead_sponsor":"HRYZ Biotech Co.","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HRYZ-T101"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-02-02"},{"id":"4317ceb2-4fba-4c3e-9e3a-12523bffaa99","acronym":"","url":"https://clinicaltrials.gov/study/NCT03132922","created_at":"2021-01-18T15:26:11.009Z","updated_at":"2024-07-02T16:35:22.736Z","phase":"Phase 1","brief_title":"MAGE-A4ᶜ¹º³²T for Multi-Tumor","source_id_and_acronym":"NCT03132922","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 12/27/2022","primary_completion_date":" 12/27/2022","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2024-01-22"},{"id":"6c76a251-4026-4ad4-94d6-b2b81e644662","acronym":"","url":"https://clinicaltrials.gov/study/NCT04809766","created_at":"2021-03-22T11:52:20.228Z","updated_at":"2024-07-02T16:35:24.105Z","phase":"Phase 1","brief_title":"Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT04809766","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-A • MSLN","pipe":" | ","alterations":" MSLN expression • HLA-A*02","tags":["HLA-A • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • FH-TCR-Tᴍsʟɴ • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-01-09"},{"id":"aafc6a72-033b-4470-9c1d-5d77ddce9a83","acronym":"","url":"https://clinicaltrials.gov/study/NCT05549921","created_at":"2022-09-22T15:56:31.418Z","updated_at":"2024-07-02T16:35:25.127Z","phase":"Phase 2","brief_title":"Phase II Study of TAEST16001 in Soft Tissue Sarcoma","source_id_and_acronym":"NCT05549921","lead_sponsor":"Sun Yat-sen University","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAEST16001"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 07/08/2022","start_date":" 07/08/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-12-27"},{"id":"96478ee8-ea1d-46f0-9076-86b0a0a5b146","acronym":"","url":"https://clinicaltrials.gov/study/NCT02869217","created_at":"2021-02-16T02:53:03.033Z","updated_at":"2024-07-02T16:35:26.728Z","phase":"Phase 1","brief_title":"Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors","source_id_and_acronym":"NCT02869217","lead_sponsor":"University Health Network, Toronto","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-12-08"},{"id":"2af4501d-3698-4fa1-bef4-a73d1a7b2ae3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03250325","created_at":"2021-02-16T02:53:12.531Z","updated_at":"2024-07-02T16:35:26.928Z","phase":"Phase 1/2","brief_title":"Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma","source_id_and_acronym":"NCT03250325","lead_sponsor":"Takara Bio Inc.","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • mipetresgene autoleucel (TBI-1301) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 01/23/2020","primary_completion_date":" 01/23/2020","study_txt":" Completion: 03/09/2022","study_completion_date":" 03/09/2022","last_update_posted":"2023-12-06"},{"id":"fd14e8af-6cb8-4bd3-b1fb-c8845a7616b6","acronym":"SAFE-T-HBV","url":"https://clinicaltrials.gov/study/NCT04745403","created_at":"2022-07-02T01:54:42.621Z","updated_at":"2024-07-02T16:35:28.875Z","phase":"Phase 1","brief_title":"Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)","source_id_and_acronym":"NCT04745403 - SAFE-T-HBV","lead_sponsor":"Lion TCR Pte. Ltd.","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24:02 • HLA-A*24","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24:02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LioCyx-M"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2023-11-17"}]